Mosaiques diagnostics is member/participant of a multitude of respectable consortia and research projects and during our time in the field of clinical proteomics we achieved a valued position in several renowned scientific networks.


Ageing is an inexorable homeostatic failure of largely unknown aetiology that leads to increased vulnerability to disease limiting the quality of life in the elderly and creating high costs to the society. Until recently, the daunting complexity of the ageing process, the conspicuous lack of tools to study it, and a dearth of experimentally tractable model systems have greatly hindered any hypothesis-driven reductionist approaches to understand the molecular basis of ageing. Whereas molecular and cellular damage is thought to be a cause of ageing and age-related pathologies, little is known about the molecular events that underlie ageing or determine longevity. CodAge (Chronic DNA damage in Ageing) is an integrated approach in studying the role of Chronic DNA damage in Ageing and age-related pathology.


Chromatin3D: Chromatin Dynamics in Development and Disease

...... a Marie Sklodowska Curie Actions Innovative Training Network

Most, if not all, DNA-dependent transactions must function within the context of chromatin. To do so, chromatin fibres must reversibly alternate between compact and relaxed structural states. The latter ensures that the underlying DNA sequences are properly exposed to protein complexes involved in transcription and replication, recombination or repair. Defects in DNA-templated processes are thought to be causal to a number of detrimental pathologies, including cancer.

The basic unit of chromatin is the nucleosome, which is composed of two copies of the histones H2A, H2B, H3 and H4 wrapped with 146 bp of DNA. Based on the decondensed beads-on-a-string configuration of repeating nucleosome units, complex interactions between the main units can result in the progressive condensation of the structure. Chromatin’s ability for condensation is regulated in part by post-translational modifications of the N-terminal tails of histones, including acetylation, phosphorylation, methylation and ubiquitination. Modifications of the histone tails can influence both internucleosomal and chromatin fibres interactions. They can also facilitate the recruitment of chromatin associated proteins and chromatin remodelling complexes. Thus the chromatin structure is characterized by the degree of chromatin condensation, the location within the nuclear architecture and the type of histone modifications.


BCMolMed (Molecular Medicine for Bladder Cancer) integrates complementary and multi-disciplinary expertise of two main (research-intensive SME-academia) and five associate partners with the objective to generate a state of the art training platform on application-oriented biomarker research and systems biology. Special emphasis is placed on the efficient employment of proteomics and bioinformatics techniques to clinical research, and understanding clinical phenotypes in a spherical manner, in line to main EU research priorities. Research is applied to the identification of biomarkers and molecular determinants of bladder cancer recurrence and invasiveness, (with emphasis on extracellular matrix proteins), due to its clinical significance and availability of molecular data.This integrative approach can be substantially beneficial and is expected to generate effective researchers and entrepreneurs in the fields of biomarker and drug target while providing valuable insight in bladder cancer molecular pathology and validated biomarkers.


EuroKup - European Kidney and Urine Proteomics
Kidney diseases constitute a major health threat in all societies. Proteomics is the large-scale analysis of the proteins of biological samples. Application of proteomics methodologies in the investigation of renal diseases will catalyze the development of optimal diagnostic and prognostic tests. Despite preliminary successful efforts, the interactions between the multidisciplinary teams of scientists working on kidney diseases and proteomics are still limited in Europe. EUROKUP will foster the generation of a strong and growing multi disciplinary network of scientists from at least 20 European countries, focusing on renal and urine proteomics. The objectives of the Action focus on the identification of reference clinical centers for major kidney diseases and establishment of uniform clinical databases, standardization and optimization of procedures, integration of data to systems biology approaches and dissemination of information for application to diagnostic/prognostic procedures. Multiple scientific, technological and societal benefits to the European Union are expected, including but not limited to setting the urgently needed standards for clinical proteomics and translational research and improving the clinical situation in chronic kidney diseases.



The FRAILOMIC initiative is a large scale research project aiming to identify the factors that turn frailty into disability.

The anticipated rise in the number of older people this century will inevitably be accompanied by an increase in the number of people with disabilities. Frailty, which comprises changes associated with ageing and chronic disease, usually precedes disability. Detecting frailty and intervening before it becomes disabling is more and more necessary as the population ages. Testing the clinical utility of the existing definition of frailty using a combination of clinical and laboratory biomarkers is pivotal.

The FRAILOMIC initiative is designed to use biomarkers to determine the factors that turn frailty into disability. The main objective is to develop clinical instruments to predict the risk of frailty, improve the diagnostic accuracy of frailty in day-to-day practice, and to assess the prognosis of frailty in terms of disability and other adverse outcomes.

Levels of blood and urine biomarkers will be measured in approximately 75,000 participants. These laboratory biomarkers will be combined with clinical biomarkers obtained from the same cohort to develop predictive, diagnostic and prognostic models in both the older general population and those people with attributes that confer a higher risk of frailty (e.g., cardiovascular risk factors). A selected set of biomarkers will be validated prospectively and assessed to find best fit models, which will guide the development of ready-to-use kits to be used in the clinical setting.


HOMAGE (Heart OMics in AGEing) regroups a unique team of experts from both academia and industry sectors to investigate heart failure (HF). HOMAGE aims at using “omics”-based technologies to identify biomarkers that reflect specific pathological pathways leading to HF, validate the predictive value of these biomarkers, and demonstrate the feasibility of an “omics”-based approach for patient stratification for personalised medicine. This approach can be beneficial in the management of HF.


Diabetes mellitus affects almost 10% of the European population. The number of patients has increased significantly within the last years and the expenditure on patients with diabetes accounts for 15% of the European health care budget expenditure. Diabetic nephropathy is one of the major complications. In progress of disease, glomerular filtration rate reduces gradually over a period of months or years. This eventually leads to end-stage renal disease requiring renal replacement therapy i.e. dialysis and/or kidney transplantation. PRIORITY is a European research project aiming at the early identification of patients at risk for subsequent preventive therapy and analysis of its effects.


The renal tract (kidneys, the ureters, bladder) is a complex organ system crucial for maintaining the body homeostasis. This organ system arises from different precursor pools through a complex program of patterning, differentiation and morphogenesis in embryonic development. Alteration of this program leads to renal tract malformations (RTM) that are incompatible with a healthy life. While some of these RTM can be surgically corrected, others develop into chronic entities that may lead to renal failure; the burden for the patients and for the socio-economic impact for the health systems is immense. Although congenital RTM are amongst the most frequent human birth defects, the different programs that direct normal and pathological development have remained poorly understood. The RENALTRACT project aims to address these deficits and provide a better understanding of the programs that underlie RTM and provide solutions to clinical problems. This shall be achieved by using a multidisciplinary team approach with partners working in complementary disciplines (developmental biology, renal physiology, Omics, clinical medicine).



EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analysing a panel of biomarkers, including genetic, proteomic and metabolomic markers together with markers of inflammation, oxidative stress and cardiac remodelling. EU-MASCARA will rigorously validate biomarkers that have been proposed to be associated with cardiovascular disease and risk across different disease entities and also in independent general population samples. The most robust biomarkers will be implemented in novel biochip based assays for clinical use. The consortium has partners based in the UK, Austria, Belgium, Germany, Italy, the Netherlands and Spain (total 15) and the project is due to last for 4 years.


Salmonella are Gramnegative bacterial pathogens capable of infecting a wide range of hosts, including humans, pigs, cows, chicken and even plants. Salmonella typhimurium is the causative agent of various human and animal diseases, reaching from enteritis to typhoid fever. In the SHIPREC project, we propose to identify protein-protein interactions and pathways as a means to understand the crosstalk between plant, animal or human hosts and Salmonella.


SysKid - A Collaborative research Project to Fight Chronic Kidney Disease
SysKid (Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment) a large-scale integrating European research project, aims at understanding chronic kidney disease in the context of diabetes and hypertension.

European Uremic Toxin (EUTox) Work Group of the ESAO
The European Society of Artificial Organs (ESAO) decided to install work groups in several areas of progress in the field of artificial organs, such as artificial liver, heart support, apheresis and adsorption, tissue engineering, education and uremic toxins.



The collaborative EU project GENINCA focuses on novel methods of early diagnosis and treatment for cancer of colon and liver.

We will use highly sophisticated methods to characterise specific tissue samples undergoing the very early steps in the erosion of healthy cells. The tumour stem cells present within these lesions will be subjected to comprehensive molecular analysis. This will lead to a better understanding of their nascency and their characteristics which in turn will enable the development of new therapies aimed at specifically eradicating these cells and therefore to treating cancer more effectively.


InGenious HyperCare
The InGenious HyperCare Network of Excellence’s goal is that of integrating complementary but still fragmented experience in the mechanisms of blood pressure control and hypertension development, in phenotyping initiation and progression of organ damage and in exploring genetics, genomics and proteomics of proneness to hypertension and hypertension-related cardiovascular disease. A better prevention of hypertension and its cardiovascular consequences is an essential public health goal in Europe, where cardiovascular diseases are the major cause of mortality and morbility. The Network plans to integrate the research efforts of 31 research teams (including a SME) and 1 SME experienced in EC project management. A powerful instrument of integration will be the Programme of Joint Research Activities. A first group of research packages will be addressed to Mechanomics of Hypertension, i.e. identifying genetic, genomic and proteomic markers of disturbances in the major mechanisms (autonomic control, inflammation and oxidative stress, sodium handling) controlling blood pressure, as indicators of the risk of becoming hypertensive. The second group of research packages will be addressed to Mechanomics of Hypertension-Related Diseases, i.e. identifying the genetic, genomic and proteomic markers of the risk of developing a hypertension-related event (stroke, renal dysfunction, heart failure). Through these activities the Network will build up large integrated platforms of common phenotypes, genotypes and proteomic data in hypertensives, and assemble unique sets of comprehensive databases. Spreading of excellence beyond the Network will be done with the support of the European Society of Hypertension. The activity of the Network will continue after end of the EC funding, with the objective of contributing better diagnostic tools to identify subjects prone to hypertension, and patients prone to hypertension complications, with obvious benefits for health care in Europe.